-
公开(公告)号：US20220193048A1
公开(公告)日：2022-06-23
申请号：US17600977
申请日：2020-04-05
申请人： Universite De Bretagne Occidentale , Centre Hospitalier Regional Et Universitaire De Brest , INSERM (Institut National De La Sante Et De La Recherche Medicale)
IPC分类号： A61K31/438 , A61K38/05 , A61P25/02 , C12N5/071 , C12N5/0793 , G01N33/50
摘要： The present invention relates to the treatment of sensory neuropathy induced by a marine neurotoxic poisoning. The invention further encompasses an in vitro method for producing a neuro-cutaneous model allowing to study the cellular and/or molecular mechanisms involved in said neuropathy, a neuro-cutaneous model obtainable according to said method, and applications thereof.
-
公开(公告)号：US20180000447A1
公开(公告)日：2018-01-04
申请号：US15544807
申请日：2015-12-17
CPC分类号： A61B8/4245 , A61B8/0875 , A61B8/4218 , A61B8/4427 , A61B8/4477 , A61B8/462 , A61B8/5223 , A61B2034/2063 , A61F2/32 , A61F2/4657 , A61F2002/4668
摘要： An ultrasound measuring device includes: a support bearing two ultrasound probes movable relative to each other by slide link, each of the two probes being movable relative to the support by ball-joint link, wherein the probes are capable of simultaneously acquiring two ultrasound images. The device includes a first set of measuring elements to measure a relative positioning of the probes, including one travel sensor and at least two orientation sensors. The device includes a second set of measuring elements to measure a positioning of the device relative to a reference plane, including at least one orientation sensor. The device localizes at least one point of interest on each of the two ultrasound images, and processes data coming from the first and second measuring elements, delivering a relative spatial position of the points of interest located in the images.
-
公开(公告)号：US11458118B2
公开(公告)日：2022-10-04
申请号：US16606236
申请日：2018-04-20
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE BRETAGNE OCCIDENTALE , ETABLISSEMENT FRANÇAIS DU SANG (EFS) , CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE BREST
IPC分类号： A61K31/40 , A61P11/00 , A61K9/00 , C12N15/113
摘要： Activating transcription factor 6 (ATF6) is involved in cystic fibrosis transmembrane conductance regulator (CFTR) repression and understanding this inhibitory mechanism is of great interest to develop a therapeutic approach based on UPR regulation. Using site-1 protease (S1P) inhibitor (e.g. PF-429242) the inventors showed that both membrane localization and function of F508del-CFTR are partially restored. Accordingly, the present invention relates to a method of treating a disease associated with reduced CFTR function in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a S1P inhibitor.
-
公开(公告)号：US11364271B2
公开(公告)日：2022-06-21
申请号：US17049221
申请日：2019-04-19
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , Etablissement Français du Sang (EFS) , Université de Bretagne Occidentale , Centre Hospitalier Regional et Universitaire de Brest
发明人： Rozenn Le Berre , Marie-Sarah Fangous , Gwenaelle Le Blay , Geneviève Hery-Arnaud , Rosyne Lagrafeuille
IPC分类号： A01N63/00 , A61K35/747 , A61P31/04 , A61P11/00
摘要： Pseudomonas aeruginosa (PA) leads to chronic respiratory infections especially in patients with cystic fibrosis patients and chronic obstructive pulmonary disease (COPD), characterized by a high morbidity. After screening Lactobacilli coming from CF expectoration, on their capacity to inhibit two Pseudomonas aeruginosa (PA) virulence factors (elastase, pyocyanin), the inventors evaluated the effect of intranasal administration of Lactobacilli on PA murine pneumonia. The primary outcome was the bacterial lung load 24 hours after PA induced pneumonia. To understand the role of Lactobacillus, the chemokines, the pro and anti-inflammatory BAL rates were also measured. The administration of Lactobacilli cocktail 18 h prior the PA lung infection decreases significantly the lung bacterial load at 24 h post-infection. Although the mechanisms need to be deeply explored, an immunomodulation effect may be involved, notably through the recruitment of neutrophils. Thus the present relates to a method of treating a Pseudomonas aeruginosa respiratory tract infection in a patient in need thereof comprising administering to the patient's respiratory tract a therapeutically effective amount of at least one Lactobacillus strain.
-
公开(公告)号：US20210017584A1
公开(公告)日：2021-01-21
申请号：US17043100
申请日：2019-03-28
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE BREST , UNIVERSITÉ DE BRETAGNE OCCIDENTALE , INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT , ETABLISSEMENT FRANÇAIS DU SANG (EFS)
发明人： Geneviève HERY-ARNAUD , Jérôme MOUNIER , Charles-Antoine GUILLOUX , Patricia LEPAGE , Stanislas MONDOT , Marlène KERAVEC
摘要： The present invention relates to methods for predicting the risk of developing pulmonary colonization/infection by P. aeruginosa. The inventors analyzed the respiratory tract microbiota from 65 patients sputum samples and compared microbiota data. The inventors found that patients that will remain uninfected from P. aeruginosa exhibited 3-fold higher abundance of Porphyromonas catoniae compared to the other groups. In particular, the present invention relates to a method for predicting the risk of developing pulmonary colonization/infection by P. aeruginosa in a subject suffering from cystic fibrosis (CF) comprising measuring the abundance of Porphyromonas catoniae in a biological sample obtained from said subject.
-
公开(公告)号：US11903982B2
公开(公告)日：2024-02-20
申请号：US17740819
申请日：2022-05-10
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , Etablissement Français du Sang (EFS) , Université de Bretagne Occidentale , Centre Hospitalier Regional et Universitaire de Brest
发明人： Rozenn Le Berre , Marie-Sarah Fangous , Gwenaelle Le Blay , Geneviève Hery-Arnaud , Rosyne Lagrafeuille
IPC分类号： A01N63/00 , A61K35/747 , A61P31/04 , A61P11/00
CPC分类号： A61K35/747 , A61P11/00 , A61P31/04
摘要： Pseudomonas aeruginosa (PA) leads to chronic respiratory infections especially in patients with cystic fibrosis patients and chronic obstructive pulmonary disease (COPD), characterized by a high morbidity. After screening Lactobacilli coming from CF expectorations, on their capacity to inhibit two Pseudomonas aeruginosa (PA) virulence factors (elastase, pyocyanin), the inventors evaluated the effect of intranasal administration of Lactobacilli on PA murine pneumonia. The primary outcome was the bacterial lung load 24 hours after PA induced pneumonia. To understand the role of Lactobacillus, the chemokines, the pro and anti-inflammatory BAL rates were also measured. The administration of Lactobacilli cocktail 18 h prior the PA lung infection decreases significantly the lung bacterial load at 24 h post-infection. Although the mechanisms need to be deeply explored, an immunomodulation effect may be involved, notably through the recruitment of neutrophils. Thus the present relates to a method of treating a Pseudomonas aeruginosa respiratory tract infection in a patient in need thereof comprising administering to the patient's respiratory tract a therapeutically effective amount of at least one Lactobacillus strain.
-
公开(公告)号：US20220331379A1
公开(公告)日：2022-10-20
申请号：US17740819
申请日：2022-05-10
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , Etablissement Français du Sang (EFS) , Université de Bretagne Occidentale , Centre Hospitalier Regional et Universitaire de Brest
发明人： Rozenn LE BERRE , Marie-Sarah FANGOUS , Gwenaelle LE BLAY , Geneviève HERY-ARNAUD , Rosyne LAGRAFEUILLE
IPC分类号： A61K35/747 , A61P31/04 , A61P11/00
摘要： Pseudomonas aeruginosa (PA) leads to chronic respiratory infections especially in patients with cystic fibrosis patients and chronic obstructive pulmonary disease (COPD), characterized by a high morbidity. After screening Lactobacilli coming from CF expectorations, on their capacity to inhibit two Pseudomonas aeruginosa (PA) virulence factors (elastase, pyocyanin), the inventors evaluated the effect of intranasal administration of Lactobacilli on PA murine pneumonia. The primary outcome was the bacterial lung load 24 hours after PA induced pneumonia. To understand the role of Lactobacillus, the chemokines, the pro and anti-inflammatory BAL rates were also measured. The administration of Lactobacilli cocktail 18 h prior the PA lung infection decreases significantly the lung bacterial load at 24 h post-infection. Although the mechanisms need to be deeply explored, an immunomodulation effect may be involved, notably through the recruitment of neutrophils. Thus the present relates to a method of treating a Pseudomonas aeruginosa respiratory tract infection in a patient in need thereof comprising administering to the patient's respiratory tract a therapeutically effective amount of at least one Lactobacillus strain.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.014 秒)
